 LCCC 1128: OPEN LABEL PHASE II TRIAL OF THE BRAF INHIBITOR DABRAFENIB AND THE MEK INHIBITOR TRAMETINIB IN UNRESECTABLE STAGE III AND STAGE IV BRAF MUTANT MELANOMA; CORRELATION OF RESISTANCE WITH THE KINOME AND FUNCTIONAL MUTATIONS: 